These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6889460)

  • 1. Epileptic seizures associated with cisplatin administration.
    Mead GM; Arnold AM; Green JA; Macbeth FR; Williams CJ; Whitehouse JM
    Cancer Treat Rep; 1982 Sep; 66(9):1719-22. PubMed ID: 6889460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cis-diammino-dichloro-platinum therapy of cancers; phase II therapeutic trial].
    Hayat M; Bayssas M; Brulé G; Cappelaere P; Cattan A; Chauvergne J; Clavel B; Gouveia J; Guerrin J; Pommatau E; Muggia F; Mathé G
    Nouv Presse Med; 1979 Mar; 8(15):1231-4. PubMed ID: 375187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemotherapy of testicular cancer, with special reference to cisplatin therapy].
    Kiriyama T; Soeda A
    Gan To Kagaku Ryoho; 1982 Mar; 9(3):397-14. PubMed ID: 6191698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cortical blindness and seizures possibly related to cisplatin, vinblastine, and bleomycin treatment of ovarian dysgerminoma.
    Young DC; Mitchell A; Kessler J; Christman JE
    J Am Osteopath Assoc; 1993 Apr; 93(4):502-4, 507. PubMed ID: 7683015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seizures associated with cisplatin administration.
    Brauers A; Mattelaer P; Mersdorf A; Wang J; Jakse G
    Eur Urol; 1997; 32(1):118-20. PubMed ID: 9266243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
    Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
    J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891.
    Rogers PC; Olson TA; Cullen JW; Billmire DF; Marina N; Rescorla F; Davis MM; London WB; Lauer SJ; Giller RH; Cushing B; ;
    J Clin Oncol; 2004 Sep; 22(17):3563-9. PubMed ID: 15337806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-based chemotherapy in dysgerminoma of the ovary: thirteen-year experience at the Institut Gustave Roussy.
    Culine S; Lhomme C; Kattan J; Duvillard P; Michel G; Gerbaulet A; Droz JP
    Gynecol Oncol; 1995 Sep; 58(3):344-8. PubMed ID: 7672699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer.
    Schilsky RL; Barlock A; Ozols RF
    Cancer Treat Rep; 1982 Sep; 66(9):1767-9. PubMed ID: 6889461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study.
    Dimopoulos MA; Papadopoulou M; Andreopoulou E; Papadimitriou C; Pavlidis N; Aravantinos G; Aspropotamitis A; Anagnostopoulos A; Fountzilas G; Michalas S; Pectacides D
    Gynecol Oncol; 1998 Jul; 70(1):70-4. PubMed ID: 9698477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [First therapeutic experience with cis-platinum(II)diamindichloride (NSC 119875) in metastasizing ovarian and testicular carcinoma].
    Cavalli F; Sonntag RW; Ryssel HJ; Tschopp L; Brunner KW
    Schweiz Med Wochenschr; 1976 May; 106(22):754-7. PubMed ID: 996494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention of cisplatin nephrotoxicity in cancer: adjusting the dosage with a computerized chrono-pump].
    Gestin-Boyer C; René C; Cupissol D; Tep A; Bressolle F; Bres J; Brun S; Serrou B; Pujol H
    C R Seances Soc Biol Fil; 1989; 183(3):263-8. PubMed ID: 2532561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy.
    Pectasides D; Pectasides E; Papaxoinis G; Skondra M; Gerostathou M; Karageorgopoulou S; Kamposioras C; Tountas N; Koumarianou A; Psyrri A; Macheras A; Economopoulos T
    J Androl; 2009; 30(3):280-6. PubMed ID: 19136393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A; Blessing J; Bender D; Mannel R; Morgan M;
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin: an anti-tumour agent.
    Drug Ther Bull; 1979 Dec; 17(25):99-100. PubMed ID: 575631
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study.
    Dimopoulos MA; Papadimitriou C; Hamilos G; Efstathiou E; Vlahos G; Rodolakis A; Aravantinos G; Kalofonos H; Kouroussis C; Gika D; Skarlos D; Bamias A
    Gynecol Oncol; 2004 Dec; 95(3):695-700. PubMed ID: 15581984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.